vs
达尔科技（DIOD）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是达尔科技的2.0倍（$772.1M vs $391.6M），Revvity净利率更高（12.7% vs 2.6%，领先10.1%），达尔科技同比增速更快（15.4% vs 5.9%），Revvity自由现金流更多（$161.8M vs $12.4M），过去两年达尔科技的营收复合增速更高（13.9% vs 9.0%）
达尔科技是一家全球性半导体制造商，主营分立器件、模拟及混合信号半导体产品的设计、生产与销售，产品广泛应用于汽车、工业、消费电子、计算及通信基础设施等核心领域，服务全球各地客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DIOD vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$391.6M
营收增速更快
DIOD
高出9.6%
5.9%
净利率更高
RVTY
高出10.1%
2.6%
自由现金流更多
RVTY
多$149.4M
$12.4M
两年增速更快
DIOD
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $391.6M | $772.1M |
| 净利润 | $10.2M | $98.4M |
| 毛利率 | 31.1% | — |
| 营业利润率 | 3.4% | 14.5% |
| 净利率 | 2.6% | 12.7% |
| 营收同比 | 15.4% | 5.9% |
| 净利润同比 | 23.8% | 3.9% |
| 每股收益（稀释后） | $0.23 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DIODRVTY
| Q4 25 | $391.6M | $772.1M | ||
| Q3 25 | $392.2M | $698.9M | ||
| Q2 25 | $366.2M | $720.3M | ||
| Q1 25 | $332.1M | $664.8M | ||
| Q4 24 | $339.3M | $729.4M | ||
| Q3 24 | $350.1M | $684.0M | ||
| Q2 24 | $319.8M | $691.7M | ||
| Q1 24 | $302.0M | $649.9M |
净利润DIODRVTY
| Q4 25 | $10.2M | $98.4M | ||
| Q3 25 | $14.3M | $46.7M | ||
| Q2 25 | $46.1M | $53.9M | ||
| Q1 25 | $-4.4M | $42.2M | ||
| Q4 24 | $8.2M | $94.6M | ||
| Q3 24 | $13.7M | $94.4M | ||
| Q2 24 | $8.0M | $55.4M | ||
| Q1 24 | $14.0M | $26.0M |
毛利率DIODRVTY
| Q4 25 | 31.1% | — | ||
| Q3 25 | 30.7% | 53.6% | ||
| Q2 25 | 31.5% | 54.5% | ||
| Q1 25 | 31.5% | 56.5% | ||
| Q4 24 | 32.7% | — | ||
| Q3 24 | 33.7% | 56.3% | ||
| Q2 24 | 33.6% | 55.7% | ||
| Q1 24 | 33.0% | 54.6% |
营业利润率DIODRVTY
| Q4 25 | 3.4% | 14.5% | ||
| Q3 25 | 3.0% | 11.7% | ||
| Q2 25 | 2.6% | 12.6% | ||
| Q1 25 | 0.4% | 10.9% | ||
| Q4 24 | 3.5% | 16.3% | ||
| Q3 24 | 6.2% | 14.3% | ||
| Q2 24 | 1.2% | 12.4% | ||
| Q1 24 | 4.3% | 6.8% |
净利率DIODRVTY
| Q4 25 | 2.6% | 12.7% | ||
| Q3 25 | 3.6% | 6.7% | ||
| Q2 25 | 12.6% | 7.5% | ||
| Q1 25 | -1.3% | 6.4% | ||
| Q4 24 | 2.4% | 13.0% | ||
| Q3 24 | 3.9% | 13.8% | ||
| Q2 24 | 2.5% | 8.0% | ||
| Q1 24 | 4.6% | 4.0% |
每股收益（稀释后）DIODRVTY
| Q4 25 | $0.23 | $0.86 | ||
| Q3 25 | $0.31 | $0.40 | ||
| Q2 25 | $0.99 | $0.46 | ||
| Q1 25 | $-0.10 | $0.35 | ||
| Q4 24 | $0.18 | $0.77 | ||
| Q3 24 | $0.30 | $0.77 | ||
| Q2 24 | $0.17 | $0.45 | ||
| Q1 24 | $0.30 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $377.0M | $919.9M |
| 总债务越低越好 | $25.7M | — |
| 股东权益账面价值 | $1.9B | $7.3B |
| 总资产 | $2.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资DIODRVTY
| Q4 25 | $377.0M | $919.9M | ||
| Q3 25 | $386.4M | $931.4M | ||
| Q2 25 | $327.3M | $991.8M | ||
| Q1 25 | $343.9M | $1.1B | ||
| Q4 24 | $316.1M | $1.2B | ||
| Q3 24 | $319.3M | $1.2B | ||
| Q2 24 | $273.9M | $2.0B | ||
| Q1 24 | $276.0M | $1.7B |
总债务DIODRVTY
| Q4 25 | $25.7M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $26.4M | — | ||
| Q1 25 | $20.5M | — | ||
| Q4 24 | $20.7M | — | ||
| Q3 24 | $22.2M | — | ||
| Q2 24 | $20.3M | — | ||
| Q1 24 | $20.9M | — |
股东权益DIODRVTY
| Q4 25 | $1.9B | $7.3B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.8B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.7B | $7.8B |
总资产DIODRVTY
| Q4 25 | $2.4B | $12.2B | ||
| Q3 25 | $2.5B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B | ||
| Q1 24 | $2.4B | $13.4B |
负债/权益比DIODRVTY
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $12.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 3.2% | 21.0% |
| 资本支出强度资本支出/营收 | 6.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.74× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $137.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DIODRVTY
| Q4 25 | $38.1M | $182.0M | ||
| Q3 25 | $79.1M | $138.5M | ||
| Q2 25 | $41.5M | $134.3M | ||
| Q1 25 | $56.7M | $128.2M | ||
| Q4 24 | $81.8M | $174.2M | ||
| Q3 24 | $54.4M | $147.9M | ||
| Q2 24 | $14.4M | $158.6M | ||
| Q1 24 | $-31.1M | $147.6M |
自由现金流DIODRVTY
| Q4 25 | $12.4M | $161.8M | ||
| Q3 25 | $62.8M | $120.0M | ||
| Q2 25 | $21.1M | $115.5M | ||
| Q1 25 | $40.8M | $112.2M | ||
| Q4 24 | $62.1M | $149.8M | ||
| Q3 24 | $39.4M | $125.6M | ||
| Q2 24 | $-3.5M | $136.6M | ||
| Q1 24 | $-51.5M | $129.7M |
自由现金流率DIODRVTY
| Q4 25 | 3.2% | 21.0% | ||
| Q3 25 | 16.0% | 17.2% | ||
| Q2 25 | 5.8% | 16.0% | ||
| Q1 25 | 12.3% | 16.9% | ||
| Q4 24 | 18.3% | 20.5% | ||
| Q3 24 | 11.2% | 18.4% | ||
| Q2 24 | -1.1% | 19.7% | ||
| Q1 24 | -17.1% | 20.0% |
资本支出强度DIODRVTY
| Q4 25 | 6.6% | 2.6% | ||
| Q3 25 | 4.2% | 2.6% | ||
| Q2 25 | 5.6% | 2.6% | ||
| Q1 25 | 4.8% | 2.4% | ||
| Q4 24 | 5.8% | 3.4% | ||
| Q3 24 | 4.3% | 3.3% | ||
| Q2 24 | 5.6% | 3.2% | ||
| Q1 24 | 6.7% | 2.7% |
现金转化率DIODRVTY
| Q4 25 | 3.74× | 1.85× | ||
| Q3 25 | 5.54× | 2.97× | ||
| Q2 25 | 0.90× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 9.93× | 1.84× | ||
| Q3 24 | 3.95× | 1.57× | ||
| Q2 24 | 1.80× | 2.87× | ||
| Q1 24 | -2.22× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
